Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1308 • ACR Convergence 2021
Higher Prevalence of Echocardiographic Abnormalities in Psoriatic Arthritis and Rheumatoid Arthritis Patients Compared to Controls
Alejandra Rodriguez-Romero, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Natalia Guajardo-Jauregui, Julieta Loya-Acosta, Alejandro Meza-Garza, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with cardiovascular abnormalities. The echocardiography is a non-invasive tool useful in the detection of cardiac…
Abstract Number: 1335 • ACR Convergence 2021
Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Laura Coates¹, Christopher Ritchlin², Laure Gossec³, Philip S Helliwell⁴, Proton Rahman⁵, Elizabeth Hsia⁶, Alexa Kollmeier⁷, Xie Xu⁶, Chetan Karyekar⁸, May Shawi⁹, Wim Noel¹⁰, Yusang Jiang⁶, Shihong Sheng⁶, Yanli Wang⁶ and Philip Mease¹¹, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ³Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen R&D, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ¹⁰Janssen Pharmaceutica, Vilvoorde, Belgium, ¹¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody specific to the p19-subunit of interleukin-23. GUS significantly improved signs and symptoms of PsA through Week 24,…
Abstract Number: 1352 • ACR Convergence 2021
Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study
Atul Deodhar¹, Miroslawa Nowak², June Ye², Tom Lehman², Lan Wei², Subhashis Banerjee² and Philip Mease³, ¹Oregon Health & Science University, Portland, OR, ²Bristol Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: PsA presents with heterogeneous clinical manifestations including joint pain, enthesitis, dactylitis, and skin and nail lesions. Treatment guidelines recommend that PsA patients (pts) who…
Abstract Number: 1700 • ACR Convergence 2021
Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib
Céleste van der Togt¹, Lise Verhoef², Nathan den Broeder³, Rob ter Heine³, Bart van den Bemt⁴ and Alfons den Broeder⁵, ¹Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ⁴Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁵Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tofacitinib is an effective, yet costly, drug for treatment of RA and PsA. Tofacitinib is metabolized mainly by the cytochrome P450-enzyme CYP3A4, and the…
Abstract Number: 1787 • ACR Convergence 2021
What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden: A Post Hoc Analysis of the ASAS-PerSpA International Study
Nelly Ziade¹, Joe Rassi², Bassel Elzorkany³, Clementina López Medina⁴, Sherif Gamal³, Sani Hlais⁵, Maxime Dougados⁶ and Xenofon Baraliakos⁷, ¹Rheumatology Department, Saint-Joseph Medical University and Hotel-Dieu de France Hospital, Beirut, Lebanon, ²Department of Orthopedic Surgery, Hotel-Dieu de France, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon, ³Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Department of Family Medicine, American University of Beirut/ Saint-Joseph University, Beirut, Lebanon, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Peripheral spondyloarthritis (pSpA) shows features that overlap with psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and other forms of SpA and is unsatisfactorily defined despite…
Abstract Number: 1804 • ACR Convergence 2021
Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis
Philip Mease¹, Peter Foley², Kristian Reich³, Soumya Chakravarty⁴, May Shawi⁵, Ya-Wen Yang⁶, Megan Miller⁷, Alexa Kollmeier⁸, Xie Xu⁷, Jenny Yu⁷, Yanli Wang⁷, Shihong Sheng⁷, Yin You⁷ and Iain McInnes⁹, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²University of Melbourne, Carlton, Australia, ³University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁴Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁵Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁶Janssen Global Services, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody that specifically binds to the p19 subunit of IL-23, demonstrated efficacy and a favorable safety profile in active…
Abstract Number: 1822 • ACR Convergence 2021
Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Peter C Taylor¹, Andrew G Bushmakin², Joseph C Cappelleri², Pamela Young³, Rebecca Germino², Joseph Merola⁴ and Gil Yosipovitch⁵, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁵University of Miami Miller School, Florida, FL
Background/Purpose: Dermatologic symptoms of PsA can substantially impact patient (pt) health‑related quality of life (HRQoL);1 itch is the most commonly reported, and among the most…
Abstract Number: 1943 • ACR Convergence 2021
Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial
Xenofon Baraliakos¹, Effie Pournara², Laura Coates³, Victoria Navarro-Compán⁴, Roisin White⁵, Barbara Schulz² and Robert Landewé⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Axial psoriatic arthritis (PsA) is the only one of the PsA manifestations, still not clearly defined, with no currently available universally acceptable clinical and…
Abstract Number: L03 • ACR Convergence 2020
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Jonghyeon Kim⁶, Shalabh Singhal⁶, Miroslawa Nowak⁶ and Subhashis Banerjee⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Leiden University Medical Center, Leiden, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by key cytokines involved in psoriatic arthritis (PsA) pathophysiology. Deucravacitinib (BMS-986165) is a…
Abstract Number: 0155 • ACR Convergence 2020
Changes in Patient-Reported Outcome (PRO) Scores for Nausea and Fatigue Following Weekly Methotrexate Dose in a Real-World Sample of RA and PsA Patients in the ArthritisPower Registry
William Nowell¹, Elaine Karis², Kelly Gavigan³, Laura Stradford³, Scott Stryker², Huifeng Yun⁴, Shilpa Venkatachalam⁵, Gregory Kricorian², Lang Chen⁴, Hong Zhao⁶, Fenglong Xie⁶ and Jeffrey R Curtis⁴, ¹Global Healthy Living Foundation, New York City, NY, ²Amgen Inc., Thousand Oaks, CA, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is frequently used in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) because of its beneficial effects in both populations. Despite…
Abstract Number: 0314 • ACR Convergence 2020
Accuracy of Physical Examination to Detect Synovial and Extra-synovial Pathologies in Psoriatic Arthritis in Comparison to Ultrasonography
Ummugulsum Gazel¹, Dilek Solmaz², Gizem Ayan³, Catherine Ivory⁴, Jacob Karsh⁴ and Sibel Aydin⁵, ¹University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, ottawa, Canada, ²Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, TURKEY, Izmir, Turkey, ³University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa Hospital Research Institute, OTTAWA, ON, Canada, ⁴University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa, ON, Canada, ⁵University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: The aim of this study to explore the comparison of physical examination (PE) and ultrasound (US) detected synovial and extra-synovial pathologies of the hands…
Abstract Number: 0330 • ACR Convergence 2020
Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors
Timothy Kwok¹, Mitchell Sutton², Daniel Pereira², Vinod Chandran³ and Dafna Gladman³, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Despite optimal medical therapy, joint space disease and skeletal damage persists in a subset of patients with PsA, many of whom requiring musculoskeletal (MSK)…
Abstract Number: 0349 • ACR Convergence 2020
Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year
Christopher Ritchlin¹, Proton Rahman², Philip Helliwell³, Wolf-Henning Boehncke⁴, Iain McInnes⁵, Alice Gottlieb⁶, Shelly Kafka⁷, Alexa Kollmeier⁸, Elizabeth Hsia⁹, Xie Xu¹⁰, May Shawi¹¹, Shihong Sheng¹², Prasheen Agarwal¹², Bei Zhou¹², Paraneedharan Ramachandran¹³ and Philip Mease¹⁴, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ¹⁰Janssen Research & Development, LLC, San Marcos, CA, ¹¹Janssen Global Services, LLC, Toronto, ON, Canada, ¹²Janssen Research & Development, LLC, Spring House, PA, ¹³Janssen Research & Development, LLC, Horsham, ¹⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2, two double-blind, phase 3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs…
Abstract Number: 0377 • ACR Convergence 2020
Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Lihi Eder¹, Dafna Gladman², Sibel Zehra Aydin³, Alexis Ogdie⁴, Harry Shi⁵, Pierre-Alexandre Landry⁶ and Rayana Luna⁶, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada, ⁴Division of Rheumatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Canada ULC, Kirkland, Canada
Background/Purpose: Studies indicate that sex (male vs female) is predictive of outcomes with PsA treatments, such as TNF inhibitors (TNFi).1 Tofacitinib is an oral JAK…
Abstract Number: 0548 • ACR Convergence 2020
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up
Maria Auxiliadora Martin-Martinez¹, Santos Castañeda², Fernando Sanchez-Alonso³, Carmen García-Gómez⁴, Carlos González_Juanatey⁵, M. Ángeles Belmonte-López⁶, Jesus Tornero-Molina⁷, José Santos-Rey⁸, Carmen Olga Sánchez-González⁹, Estefania Moreno¹⁰, Maria del puerto Moreno-Gil¹¹, Tatiana Cobo-Ibañez¹², Jose Antonio Pinto-Tasende¹³, Jesús Babío-Herráez¹⁴, Gema Bonilla¹⁵, Antonio Juan-Mas¹⁶, Francisco Manero-Ruiz¹⁷, Montserrat Romera-Baurés¹⁸, Javier Bachiller-Corral¹⁹, Eugenio Chamizo-Carmona²⁰, Javier Calvo-Catalán²¹, Raimon Sanmartí²², Celia Erausquin-Arruabarrena²³, Rosario Garcia-Vicuña²⁴, Carmen Barbadillo²⁵, Sergio Ros-Expósito²⁶, Ana Isabel Turrión²⁷, M José González-Fernández²⁸, Jose Miguel Senabre²⁹, Silvia Martínez-Pardo³⁰, Ana Ruibal-Escribano³¹, Emilio Giner-Serret³², Elisabet Berzosa-Sola³³, Julia Martínez-Barrio³⁴, Encarnación Pagán³⁵, M Enriqueta- Peiró³⁶, Sagrario Bustabad-Reyes³⁷, Alba Erra-Durán³⁸, Beatriz González Álvarez³⁹, Ana Cruz Valenciano⁴⁰, Javier Rivera-Redondo⁴¹, Manuel Moreno Ramos⁴², Sergio Rodriguez Montero⁴³, Mercedes Morcillo-Valle⁴⁴, Maria Teresa Navío⁴⁵, Maria Galindo-Izquierdo⁴⁶, Manuel Riera-Soler⁴⁷, Jordi Fiter⁴⁸, Javier Llorca⁴⁹ and Miguel Ángel González-Gay⁵⁰, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ⁴Consorci Sanitari de Terrassa, Barcelona, Spain, ⁵Hospital Lucus Augusti, Lugo, Spain, ⁶Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁷University Hospital of Guadalajara. Spain, Madrid, Madrid, Spain, ⁸Hospital Virgen de la Salud, Toledo, Spain, ⁹Hospital Sureste, Madrid, Spain, ¹⁰Universitario Vall D'hebron, Barcelona, Spain, ¹¹Complejo Hospitalario de Cáceres, Caceres, Spain, ¹²Hospital Infanta Sofia, Madrid, Spain, ¹³CHUAC, A Coruña, Spain, ¹⁴Hospital de Cabueñes, Gijón, Spain, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶Hospital Sont Llatzer, Palma de Mallorca, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁰Hospital de Merida, Badajoz, Spain, ²¹Hospital General Universitario Valencia, Valencia, Spain, ²²Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ²³Hospital de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ²⁴Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Viladecans, Barcelona, Spain, ²⁷Hospital Universitario de Salamanca, Salamanca, Spain, ²⁸Hospital Dexeus, Barcelona, Spain, ²⁹Hospital de Marina Baixa, Alicante, Spain, ³⁰H. Mutua de Terrassa, Barcelona, Catalonia, Spain, ³¹Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ³²Hospital Obispo Polanco, Teruel, Spain, ³³Hospital del Elda, Alicante, Spain, ³⁴Hospital General Universitario Gregorio Marañón, Madrid, ³⁵Hospital Los Arcos, Murcia, Spain, ³⁶Hospital Marques de Valdecilla, Santander, Spain, ³⁷Hospital Universitario Canarias, Tenerife, Spain, ³⁸Hospital San Rafael, Barcelona, Spain, ³⁹Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, ⁴⁰Hospital Severo Ochoa, Madrid, Spain, ⁴¹Instituto Provincial de Rehabilitación, Madrid, Spain, ⁴²Hospital Virgen de la Arrixaca, Murcia, Spain, ⁴³H. Virgen de Valme, Sevilla, Spain, ⁴⁴Hospital El Escorial, Madrid, Spain, ⁴⁵Hospital Infanta Leonor, Madrid, Spain, ⁴⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴⁷Hospital dos de Maig, Barcelona, Spain, ⁴⁸Hospital Universitario Son Dureta, Palma de Mallorca, Spain, ⁴⁹School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular (CV) event (CVE) in patients with chronic inflammatory rheumatic diseases…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].